Literature DB >> 9426041

Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension.

N Nagaya1, T Nishikimi, Y Okano, M Uematsu, T Satoh, S Kyotani, S Kuribayashi, S Hamada, M Kakishita, N Nakanishi, M Takamiya, T Kunieda, H Matsuo, K Kangawa.   

Abstract

OBJECTIVES: This study sought to investigate the influence of right ventricular (RV) hemodynamic variables and function on the secretion of brain natriuretic peptide (BNP) in patients with isolated RV overload.
BACKGROUND: Plasma BNP is known to increase in proportion to the degree of left ventricular (LV) overload. However, whether BNP secretion is also regulated in the presence of RV overload remains unknown.
METHODS: Plasma BNP and atrial natriuretic peptide (ANP) levels in the pulmonary artery were measured in 44 patients with RV overload: 18 with RV volume overload (RVVO) due to atrial septal defect and 26 with RV pressure overload (RVPO) due to primary or thromboembolic pulmonary hypertension. Right heart catheterization was performed in all patients. RV and LV ejection fraction, myocardial mass and volume of the four chambers were determined by using electron beam computed tomography.
RESULTS: Although both plasma BNP and ANP levels were significantly elevated in patients with RV overload compared with values in control subjects, plasma BNP and the BNP/ANP ratio were significantly higher in patients with RVPO than with RVVO (BNP 294 +/- 72 vs. 48 +/- 14 pg/ml; BNP/ANP 1.6 +/- 0.2 vs. 0.8 +/- 0.2, both p < 0.05). Plasma BNP correlated positively with mean pulmonary artery pressure (r = 0.73), total pulmonary resistance (r = 0.79), mean right atrial pressure (r = 0.79), RV end-diastolic pressure (r = 0.76) and RV myocardial mass (r = 0.71); it correlated negatively with cardiac output (r = -0.33) and RV ejection fraction (r = -0.71). Plasma BNP significantly decreased from 315 +/- 120 to 144 +/- 54 pg/ml with long-term vasodilator therapy (total pulmonary resistance decreased from 23 +/- 4 to 15 +/- 3 Wood U).
CONCLUSIONS: Plasma BNP increases in proportion to the extent of RV dysfunction in pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9426041     DOI: 10.1016/s0735-1097(97)00452-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  101 in total

Review 1.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 2.  Right ventricular failure: a novel era of targeted therapy.

Authors:  Dipanjan Banerjee; Francois Haddad; Roham T Zamanian; Jayan Nagendran
Journal:  Curr Heart Fail Rep       Date:  2010-12

Review 3.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

4.  Effects of lesion complexity on baseline and postprocedural B-type natriuretic peptide levels in patients undergoing percutaneous coronary interventions.

Authors:  Aylin Yildirir; Sadik Acikel; Cagatay Ertan; Alp Aydinalp; Bulent Ozin; Haldun Muderrisoglu
Journal:  Tex Heart Inst J       Date:  2007

5.  N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.

Authors:  Theodoros Dimitroulas; Georgios Giannakoulas; Haralambos Karvounis; Georgios Koliakos; Tilemahos Sfetsios; Hara Dimitroula; Loukas Settas
Journal:  Clin Rheumatol       Date:  2008-01-18       Impact factor: 2.980

Review 6.  Pulmonary arterial hypertension: the clinical syndrome.

Authors:  Yen-Chun Lai; Karin C Potoka; Hunter C Champion; Ana L Mora; Mark T Gladwin
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

7.  Elevated N-terminal pro-B-type natriuretic peptide levels: the effect of chronic obstructive pulmonary disease.

Authors:  Yvette R B M van Gestel; Don D Sin; Don Poldermans
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

8.  The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill.

Authors:  Guangxi Li; Craig E Daniels; Marija Kojicic; Tami Krpata; Greg A Wilson; Jeffrey L Winters; S Breanndan Moore; Ognjen Gajic
Journal:  Transfusion       Date:  2008-10-14       Impact factor: 3.157

9.  Surgical strategy for severe aortic hypoplasia and aortic stenosis with ventricular septal defect and normal left ventricle.

Authors:  Takahiro Tomoyasu; Norihiko Oka; Takashi Miyamoto; Tadashi Kitamura; Keiichi Itatani; Nobuyuki Inoue; Masahiro Ishii; Kagami Miyaji
Journal:  Pediatr Cardiol       Date:  2012-12-19       Impact factor: 1.655

Review 10.  Pulmonary hypertension in bronchopulmonary dysplasia.

Authors:  Sara K Berkelhamer; Karen K Mestan; Robin H Steinhorn
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.